PT  - JOURNAL ARTICLE
AU  - David Simon
AU  - Koray Tascilar
AU  - Filippo Fagni
AU  - Gerhard Krönke
AU  - Arnd Kleyer
AU  - Christine Meder
AU  - Raja Atreya
AU  - Moritz Leppkes
AU  - Andreas E Kremer
AU  - Andreas Ramming
AU  - Milena L Pachowsky
AU  - Florian Schuch
AU  - Monika Ronneberger
AU  - Stefan Kleinert
AU  - Axel J Hueber
AU  - Karin Manger
AU  - Bernhard Manger
AU  - Carola Berking
AU  - Michael Sticherling
AU  - Markus F Neurath
AU  - Georg Schett
TI  - SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
AID  - 10.1136/annrheumdis-2021-220461
DP  - 2021 Oct 01
TA  - Annals of the Rheumatic Diseases
PG  - 1312--1316
VI  - 80
IP  - 10
4099  - http://ard.bmj.com/content/80/10/1312.short
4100  - http://ard.bmj.com/content/80/10/1312.full
SO  - Ann Rheum Dis2021 Oct 01; 80
AB  - Objectives To better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs).Methods Patients and controls from a large COVID-19 study, with (1) no previous history of COVID-19, (2) negative baseline anti-SARS-CoV-2 IgG test and (3) SARS-CoV-2 vaccination at least 10 days before serum collection were measured for anti-SARS-CoV-2 IgG. Demographic, disease-specific and vaccination-specific data were recorded.Results Vaccination responses from 84 patients with IMID and 182 controls were analysed. While all controls developed anti-SARS-CoV-2 IgG, five patients with IMID failed to develop a response (p=0.003). Moreover, 99.5% of controls but only 90.5% of patients with IMID developed neutralising antibody activity (p=0.0008). Overall responses were delayed and reduced in patients (mean (SD): 6.47 (3.14)) compared with controls (9.36 (1.85); p<0.001). Estimated marginal means (95% CI) adjusted for age, sex and time from first vaccination to sampling were 8.48 (8.12–8.85) for controls and 6.90 (6.45–7.35) for IMIDs. Significantly reduced vaccination responses pertained to untreated, conventionally and anticytokine treated patients with IMID.Conclusions Immune responses against the SARS-CoV-2 are delayed and reduced in patients with IMID. This effect is based on the disease itself rather than concomitant treatment.All data relevant to the study are included in the article or uploaded as online supplemental information. Data are under embargo by local authorities if not included into the manuscript.